Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug2556	Transplant patient Wiki	1.00
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Measure: The incidence of tracheal intubation or death prior to tracheal intubation

Time: From randomization to Day 28

---

Secondary Outcomes

Measure: Proportion of subjects with death from all causes

Time: From randomization to Day 28

---

Measure: Proportion of subjects intubated

Time: From randomization to Day 28

---

Measure: Number and proportion of subjects with ≥ 2‑point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale

Time: From randomization to Day 28

---

Measure: Number and proportion of subjects within each of the categories of the NIAID

Time: From randomization to Day 28

---

Measure: Proportion of subjects requiring continuous positive airway pressure (CPAP)

Time: From randomization to Day 28

---

Measure: Proportion of subjects requiring bilevel positive airway pressure (BiPAP)

Time: From randomization to Day 28

---

Measure: Proportion of subjects requiring high‑flow nasal cannula (HFNC)

Time: From randomization to Day 28

---

Measure: Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)

Time: From randomization to Day 28

---

Measure: Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score

Time: From randomization to Day 28

---

Measure: Change from Baseline in SOFA score and in the individual components of SOFA score

Time: From randomization to Day 28

---

Measure: Length of hospital stay

Time: From randomization to Day 28

---

Measure: Number and proportion of subjects experiencing Adverse Events (AEs)

Time: Up to 28 days after CSL312 or placebo administration

---

Measure: Number and proportion of subjects experiencing serious adverse events (SAEs)

Time: Up to 28 days after CSL312 or placebo administration

---

Measure: Number and proportion of subjects with adverse events of special interest (AESIs)

Time: Up to 28 days after CSL312 or placebo administration

---

Measure: Number and proportion of subjects with CSL312 induced anti‑CSL312 antibodies

Time: Up to 28 days after CSL312 or placebo administration

---

Measure: Maximum plasma concentration (Cmax) of CSL312

Time: Up to 28 days after CSL312 administration

---

Measure: Time to maximum plasma concentration (Tmax) of CSL312

Time: Up to 28 days after CSL312 administration

---

Measure: Area under the plasma concentration‑time curve from time zero to the time of the last measurable concentration (AUC0‑last) of CSL312

Time: Up to 28 days after CSL312 administration

---

Measure: Terminal half-life (T1/2) of CSL312

Time: Up to 28 days after CSL312 administration

---